500K shares at $3.05, 13 minutes after the close.
Pin the tail on him/her......
<CAPTION>
NUMBER OF SHARES PERCENTAGE OF SHARES
NAME AND ADDRESS OF BENEFICIAL OWNER(1) BENEFICIALLY OWNED(2) BENEFICIALLY OWNED(2)
- --------------------------------------- --------------------- ---------------------
<S> <C> <C>
Wells Fargo Bank Indiana, N.A.(3)....................... 3,419,015 14.4%
P.O. Box 960
Fort Wayne, IN 46801
Atlas Venture(4)........................................ 2,564,151 10.9%
222 Berkeley Street, Suite 1950
Boston, MA 02116
Oxford Bioscience Partners(5)........................... 2,115,363 9.0%
315 Post Road West
Westport, CT 06880
CIBC(6)................................................. 2,099,118 9.0%
425 Lexington Avenue, 9th Floor
New York, NY 10017
Forward Ventures(7)..................................... 1,242,324 5.3%
9255 Towne Centre Drive, Suite 300
San Diego, CA 92121
Taylor J. Crouch(8)..................................... 407,798 1.7%
Anne L. Bailey(9)....................................... 100,134 *
Colin W. Dykes, Ph.D.(10)............................... 126,160 *
Bruce L. Maloff, Ph.D.(11).............................. 36,257 *
Richard P. Shea(12)..................................... 79,323 *
</TABLE>
13
<PAGE>
<TABLE>
<CAPTION>
NUMBER OF SHARES PERCENTAGE OF SHARES
NAME AND ADDRESS OF BENEFICIAL OWNER(1) BENEFICIALLY OWNED(2) BENEFICIALLY OWNED(2)
- --------------------------------------- --------------------- ---------------------
<S> <C> <C>
David Housman, Ph.D.(13)................................ 256,619 1.1%
Philippe O. Chambon, M.D., Ph.D.(14).................... 3,965,904 16.8%
Jean-Francois Formela, M.D.(15)......................... 2,582,369 11.0%
William A. Scott, Ph.D.(16)............................. 15,377 *
Martin A. Vogelbaum(17)................................. 40,984 *
Anthony H. Wild, Ph.D.(18).............................. 108,877 *
Ellen M. Zane(19)....................................... 5,000 *
All directors and executive officers as a group (14 7,860,467 31.8%
persons)..............................................
</TABLE>
- ------------------------
* Represents beneficial ownership of less than one percent of the Company's
outstanding shares of Common Stock.
(1) Addresses are given for beneficial owners of more than 5% of the
outstanding Common Stock only. Unless otherwise indicated, the address of
each shareholder is c/o Variagenics, Inc., 60 Hampshire Street, Cambridge,
Massachusetts 02139.
(2) Shares of Common Stock that an individual or group has the right to acquire
within sixty days of April 2, 2001, pursuant to the exercise of options and
warrants or pursuant to stock purchase agreements, are deemed outstanding
for the purpose of computing the percentage ownership of such individual or
group, but are not deemed to be outstanding for the purpose of computing
the percentage ownership of any other person shown in the table.
(3) This information is based solely on a Schedule 13G filed by Wells Fargo &
Company with the Securities and Exchange Commission on March 26, 2001.
Includes 2,979,815 shares and warrants to purchase 439,200 shares held by
Wells Fargo Bank Indiana, N.A. (the "Bank"), as trustee, pursuant to a
voting trust agreement by and among the Bank, Sprout Capital VIII, L.P.,
Sprout Venture Capital, L.P., DLJ Capital Corporation, DLJ ESC II, L.P. and
Donaldson, Lufkin & Jenrette, Inc. Philippe O. Chambon, M.D., Ph.D. is a
general partner of the general partner of Sprout Capital VIII, L.P.
(4) This information is based solely on a Schedule 13G filed by Atlas Venture
Fund III, L.P. with the Securities and Exchange Commission on February 14,
2001. Includes 2,332,891 shares and warrants to purchase 188,470 shares
held by Atlas Venture Fund III, L.P. and 38,691 shares and warrants to
purchase 4,099 shares held by Atlas Venture Entrepreneurs' Fund III L.P.
Jean-Francois Formela, M.D., is a general partner of Atlas Venture.
(5) Includes 800,492 shares and warrants to purchase 62,468 shares held by
Oxford Bioscience Partners II, L.P., 599,897 shares and warrants to
purchase 46,815 shares held by Oxford Bioscience Partners (Bermuda) II,
L.P., 195,327 shares and warrants to purchase 16,206 shares held by Oxford
Bioscience Partners (Adjunct) II, L.P., and 357,583 shares and warrants to
purchase 36,575 shares held by Oxford Bioscience Partners (GS-Adjunct) II,
L.P.
(6) This information is based solely on a Schedule 13G filed by Canadian
Imperial Bank of Commerce ("CIBC") with the Securities and Exchange
Commission on February 14, 2001. Includes 1,574,339 shares held by CIBC
WMV Inc., a wholly-owned indirect subsidiary of CIBC, and 524,779 shares
held by CIBC Employee Private Equity Fund Partners, a vehicle owned by
partnerships established for the benefit of employees of CIBC to which CIBC
serves as an advisor.
14
<PAGE>
(7) This information is based solely on a Schedule 13G filed by Forward
Ventures III, L.P. with the Securities and Exchange Commission on
February 7, 2001. Includes 216,155 shares and warrants to purchase 43,364
shares held by Forward Ventures III, L.P. and 818,587 shares and warrants
to purchase 164,218 shares held by Forward Ventures III Institutional
Partners, L.P.
(8) Includes 318,586 shares issuable upon the exercise of options to purchase
Common Stock.
(9) Includes 59,429 shares issuable upon the exercise of options to purchase
Common Stock.
(10) Includes 124,516 shares issuable upon the exercise of options to purchase
Common Stock.
(11) Includes 36,257 shares issuable upon the exercise of options to purchase
Common Stock.
(12) Includes 77,952 shares issuable upon the exercise of options to purchase
Common Stock.
(13) Includes 67,185 shares issuable upon the exercise of options to purchase
Common Stock.
(14) Includes 12,075 shares issuable upon the exercise of options to purchase
Common Stock. Includes 2,442,751 shares and warrants to purchase 381,796
shares held by Wells Fargo Bank Indiana, N.A. (the "Bank"), as trustee,
pursuant to a voting trust agreement by and among the Bank, Sprout Capital
VIII, L.P., Sprout Venture Capital, L.P., DLJ Capital Corporation, DLJ ESC
II, L.P. and Donaldson, Lufkin & Jenrette, Inc. and 1,129,282 shares held
by Sprout Capital VIII, L.P. Dr. Chambon is a general partner of the
general partner of Sprout Capital VIII, L.P. and disclaims beneficial
ownership of such shares and warrants, except to the extent of his
pecuniary interest in the shares and warrants.
(15) Includes 13,218 shares issuable upon the exercise of options to purchase
Common Stock. Includes 2,371,582 shares and warrants to purchase 192,569
shares held by Atlas Venture. Dr. Formela is a general partner of Atlas
Venture and disclaims beneficial ownership of such shares and warrants,
except to the extent of his pecuniary interest in the shares and warrants.
(16) Includes 13,877 shares issuable upon the exercise of options to purchase
Common Stock.
(17) Includes 38,984 shares issuable upon the exercise of options to purchase
Common Stock.
(18) Includes 13,877 shares issuable upon the exercise of options to purchase
Common Stock.
(19) Includes 5,000 shares issuable upon the exercise of options to purchase
Common Stock.
15
<PAGE> |
